What are the differences between the U.S. FDA and Chinese SFDA approval processes? What's the standard procedure to get Chinese regulatory approval for a marketed drug elsewhere in the world? What are the special considerations related to biologics approval? What if my drug is only at phase II development in the U.S., can I start a phase II clinical trials in China?
These are fundamental questions one wants to know before deciding to enter China. We have developed a set of comprehensive databases on the Chinese healthcare system, from companies to drugs, from hospitals to doctors, and from patients to diseases. We have assembled education packages for those looking for basic information about the healthcare industry in China, such as an overview of the landscape and the regulatory approval process. We also perform targeted research projects on specific products, diseases and market conditions at our clients' request. Our understanding of the Chinese healthcare system allows us to look in the right place for the most complete and authoritative information, and our network of executives and key opinion leaders ensures that our primary research provides you with the most informed perspective in the field.
For more information on our markets research services, please contact inquiries@modularrandd.com